VOR - NASDAQ
Vor Biopharma Inc.
$13.44
-0.037%Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotvor
Total Assets
Last Annual Value
464.13M
3-Year CAGR
16%
5-Year CAGR
44%
10-Year CAGR
85%
Vor Biopharma Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Vor Biopharma Inc. NASDAQ:VOR | 464.13M | 30.3% | 13.9% | N/A | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 82.78M | 28.5% | 13.8% | 8.9% | |
 Spero Therapeutics, Inc. NASDAQ:SPRO | 68.92M | -27.7% | -16.6% | 17.5% | |
 Codexis, Inc. NASDAQ:CDXS | 147.80M | 2.7% | -9.7% | 15.3% | |
 Coherus Oncology, Inc. NASDAQ:CHRS | 258.34M | -25.7% | -17.6% | 3.8% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 168.19M | 81.2% | 9.3% | 25.1% | |
 Genelux Corporation NASDAQ:GNLX | 19.03M | -12.0% | 18.5% | N/A | |
 Heron Therapeutics, Inc. NASDAQ:HRTX | 255.88M | 4.8% | -3.5% | 14.3% | |
 OmniAb, Inc. NASDAQ:OABI | 300.91M | -7.1% | -0.2% | N/A | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 114.86M | 6.5% | 53.4% | N/A | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 209.47M | 38.4% | 3.9% | 17.0% |
Vor Biopharma Inc. Fair Value Envelope
Related Guides
Continue your VOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.